<DOC>
	<DOC>NCT01691989</DOC>
	<brief_summary>This multicenter, randomized, double-blind, placebo-controlled study will assess the efficacy, safety and tolerability of aleglitazar compared with placebo when added to a sulfonylurea monotherapy or sulfonylurea plus metformin combination therapy in patients with type 2 diabetes mellitus who are inadequately controlled with sulfonylurea alone or sulfonylurea plus metformin therapy. Patients will be randomized to receive oral doses of 150 mcg aleglitazar once daily or placebo. The anticipated time on study treatment is 26 weeks.</brief_summary>
	<brief_title>A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Adult patients, &gt;/=18 years of age Diagnosis of diabetes mellitus, type 2 Patients treated with stable sulfonylurea monotherapy or sulfonylurea plus metformin combination therapy for at least 12 weeks prior to screening HbA1c &gt;/=7% and &lt;/=9.5% at screening or within 4 weeks prior to screening and at prerandomization visit Fasting plasma glucose &lt;/=240 mg/dL at prerandomization visit Agreement to maintain diet and exercise habits during the study Patients with Type 1 diabetes mellitus, secondary diabetes, diabetes resulting from pancreatic injury, or acute metabolic diabetic complications within the past 6 months Any previous treatment with thiazolidinedione or a dual PPAR agonist Any body weight lowering or lipoproteinmodifying therapy within 12 weeks prior to screening (except stable dose of statin) Any antihyperglycemic medication other than sulfonylurea alone or in combination with metformin within 12 weeks prior to screening Symptomatic congestive heart failure classified as New York Heart Association class IIIV at screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>